VOR vs. NKE

Last updated Apr 2, 2026

Compare and contrast key facts about Vor Biopharma Inc. (VOR) and NIKE, Inc. (NKE).

Performance

VOR vs. NKE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vor Biopharma Inc. (VOR) and NIKE, Inc. (NKE). The values are adjusted to include any dividend payments, if applicable.

VOR vs. NKE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
VOR Vor Biopharma Inc.	32.95%	-41.08%	-50.67%	-66.17%	-42.77%	-69.01%
NKE NIKE, Inc.	-29.48%	-13.83%	-29.11%	-6.01%	-29.04%	15.72%

Fundamentals

Market Cap VOR : $171.67M NKE : $66.07B
EPS VOR : -$91.51 NKE : $1.52
Total Revenue (TTM) VOR : $0.00 NKE : $46.52B
Gross Profit (TTM) VOR : $0.00 NKE : $18.99B
EBITDA (TTM) VOR : -$371.64M NKE : $3.33B

Returns By Period

In the year-to-date period, VOR achieves a 32.95% return, which is significantly higher than NKE's -29.48% return.

VOR

• 1D: -2.52%
• 1M: 9.37%
• YTD: 32.95%
• 6M: -55.71%
• 1Y: 40.24%
• 3Y*: -45.53%
• 5Y*: -53.21%
• 10Y*: —

NKE

• 1D: -15.51%
• 1M: -26.85%
• YTD: -29.48%
• 6M: -39.07%
• 1Y: -29.35%
• 3Y*: -27.24%
• 5Y*: -18.33%
• 10Y*: -1.89%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VOR vs. NKE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VOR

VOR Risk / Return Rank: 60
VOR Sharpe Ratio Rank: 48
VOR Sortino Ratio Rank: 78
VOR Omega Ratio Rank: 80
VOR Calmar Ratio Rank: 47
VOR Martin Ratio Rank: 45

NKE

NKE Risk / Return Rank: 12
NKE Sharpe Ratio Rank: 12
NKE Sortino Ratio Rank: 14
NKE Omega Ratio Rank: 13
NKE Calmar Ratio Rank: 18
NKE Martin Ratio Rank: 3

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VOR vs. NKE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Vor Biopharma Inc. (VOR) and NIKE, Inc. (NKE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VOR	NKE	Difference
Sharpe ratio Return per unit of total volatility	0.22	-0.67	+0.89
Sortino ratio Return per unit of downside risk	2.01	-0.78	+2.79
Omega ratio Gain probability vs. loss probability	1.29	0.89	+0.40
Calmar ratio Return relative to maximum drawdown	0.24	-0.65	+0.90
Martin ratio Return relative to average drawdown	0.37	-1.78	+2.15
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VOR vs. NKE - Sharpe Ratio Comparison

The current VOR Sharpe Ratio is 0.22, which is higher than the NKE Sharpe Ratio of -0.67. The chart below compares the historical Sharpe Ratios of VOR and NKE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VOR	NKE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.22	-0.67	+0.89
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.46	-0.52	+0.06
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.06	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.44	0.41	-0.85

Correlation

The correlation between VOR and NKE is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VOR vs. NKE - Dividend Comparison

VOR has not paid dividends to shareholders, while NKE's dividend yield for the trailing twelve months is around 3.63%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
VOR Vor Biopharma Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NKE NIKE, Inc.	3.63%	2.53%	2.00%	1.28%	1.07%	0.68%	0.71%	0.89%	1.11%	1.18%	1.30%	0.93%

Drawdowns

VOR vs. NKE - Drawdown Comparison

The maximum VOR drawdown since its inception was -99.72%, which is greater than NKE's maximum drawdown of -75.19%. Use the drawdown chart below to compare losses from any high point for VOR and NKE.

Drawdown Indicators

	VOR	NKE	Difference
Max Drawdown Largest peak-to-trough decline	-99.72%	-75.19%	-24.53%
Max Drawdown (1Y) Largest decline over 1 year	-87.15%	-42.65%	-44.50%
Max Drawdown (5Y) Largest decline over 5 years	-99.61%	-72.98%	-26.63%
Max Drawdown (10Y) Largest decline over 10 years	—	-72.98%	—
Current Drawdown Current decline from peak	-98.39%	-72.98%	-25.41%
Average Drawdown Average peak-to-trough decline	-88.37%	-20.70%	-67.67%
Ulcer Index Depth and duration of drawdowns from previous peaks	57.96%	15.69%	+42.27%

Volatility

VOR vs. NKE - Volatility Comparison

Vor Biopharma Inc. (VOR) has a higher volatility of 28.65% compared to NIKE, Inc. (NKE) at 17.58%. This indicates that VOR's price experiences larger fluctuations and is considered to be riskier than NKE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VOR	NKE	Difference
Volatility (1M) Calculated over the trailing 1-month period	28.65%	17.58%	+11.07%
Volatility (6M) Calculated over the trailing 6-month period	102.16%	30.01%	+72.15%
Volatility (1Y) Calculated over the trailing 1-year period	187.38%	44.03%	+143.35%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	117.19%	35.64%	+81.55%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	118.01%	32.11%	+85.90%

Financials